- Report
- December 2019
- 95 Pages
Global
From €3843EUR$4,000USD£3,299GBP
- Drug Pipelines
- September 2020
- 73 Pages
Global
From €1922EUR$2,000USD£1,650GBP
- Report
- February 2024
- 89 Pages
Global
From €3500EUR$3,902USD£3,110GBP
- Report
- October 2023
- 99 Pages
Global
From €3500EUR$3,902USD£3,110GBP
- Report
- January 2024
- 90 Pages
Global
From €3500EUR$3,902USD£3,110GBP
- Report
- March 2021
Japan, United States, ... Japan, United States, Europe
From €913EUR$950USD£784GBP
- Report
- February 2020
Japan, United States, ... Japan, United States, Europe
From €913EUR$950USD£784GBP
- Report
- May 2024
- 50 Pages
Global
From €2546EUR$2,650USD£2,186GBP
- Report
- September 2022
- 293 Pages
Global
From €5506EUR$5,730USD£4,726GBP
- Report
- June 2022
- 230 Pages
Global
From €5543EUR$5,769USD£4,758GBP
- Report
- January 2020
- 165 Pages
Global
From €5160EUR$5,370USD£4,429GBP
Tacrolimus is an immunosuppressant drug used to treat immune disorders such as rheumatoid arthritis, psoriasis, and Crohn's disease. It works by inhibiting the production of certain proteins that are involved in the body's immune response. Tacrolimus is typically administered orally or intravenously, and is available in both generic and branded forms. It is also used to prevent organ rejection in transplant patients.
Tacrolimus is a widely used drug in the treatment of immune disorders, and is often prescribed in combination with other drugs. It is generally well tolerated, with few side effects. However, it can cause serious side effects, such as an increased risk of infection and an increased risk of developing certain types of cancer.
The tacrolimus market is highly competitive, with many companies offering generic and branded versions of the drug. Some of the major players in the market include Pfizer, Novartis, Merck, and Sanofi. Other companies include Mylan, Teva, and Sun Pharmaceuticals. Show Less Read more